Inovio's dMAb(TM) PD-1 Checkpoint Inhibitors Demonstrate Higher and More Prolonged Expression Compared to Native Pembrolizumab and Nivolumab Sequences In Preclinical Studies
Stock Information for Inovio Pharmaceuticals Inc.
Loading
Please wait while we load your information from QuoteMedia.